🇺🇸 FDA
Patent

US 8236821

Substituted N-phenyl-5-phenyl-pyrazolin-3-yl amides as cannabinoid receptor antagonists/inverse agonists useful for treating obesity

granted A61PA61P3/00

Quick answer

US patent 8236821 (Substituted N-phenyl-5-phenyl-pyrazolin-3-yl amides as cannabinoid receptor antagonists/inverse agonists useful for treating obesity) held by Jenrin Discovery, LLC expires Mon Aug 02 2032 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
Jenrin Discovery, LLC
Grant date
Tue Aug 07 2012 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Aug 02 2032 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
12
CPC classes
A61P, A61P3/00